Vico Therapeutics (Leiden, The Netherlands) works on RNA modulating therapies for rare neurological disorders, developing antisense oligonucleotide against spinocerebellar ataxia, Huntington’s disease and RETT syndrome. – vicotx.com
Location: Netherlands, South Holland, Leiden
Employees: 11-50
Total raised: $103.35M
Founded date: 2019
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.06.2024 | Series B | $12.35M | - |
| 06.01.2024 | Series B | $60M | - |
| 30.07.2020 | Series A | $31M | - |
Mentions in press and media 10
| Date | Title | Description |
| 13.09.2024 | Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease | First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in 40 mg dose cohort with an effect after the first dose No sustained increase in CSF neurofilament light chain (Nf-L) protein observed ... |
| 24.06.2024 | Vico Therapeutics Raises EUR11.5M in Additional Series B | Vico Therapeutics, a Leiden, The Netherlands-based clinical-stage genetic medicines company, raised EUR11.5M in the second closing of its Series B funding. Backers included Seroba, and Kurma Partners, via the Kurma Growth Opportunities Fund... |
| 26.03.2024 | Meet the companies that raised the top 8 Dutch funding rounds in Q1 2024; all are hiring right now | Read this article in: The last quarter of 2023 ended as the best quarter of the year for the Netherlands in terms of deals and total amount invested, with Q4 contributing €576M to the €1.5B total. Now, the Netherlands is closing Q1 2024 on ... |
| 06.01.2024 | Netherlands-based Vico Therapeutics raises USD 60 million in funding | Netherlands-based clinical-stage genetic medicines company developing therapies for severe neurological diseases, Vico Therapeutics raised USD 60 million in funding. The round took place on January 5, 2023. Ackermans & van Haaren led th... |
| 05.01.2024 | Dutch-based Vico Therapeutics secures €54M to develop therapies for neurological diseases | Read this article in: Leiden-based Vico Therapeutics, a Dutch genetic medicines company, secured €54M in a Series B funding round to support the development of therapies for severe neurological diseases. The round was led by Ackermans &... |
| 05.01.2024 | Vico Therapeutics Raises $60M in Series B Financing | Micah Mackison, CEO of Vico Therapeutics Vico Therapeutics, a Leiden, The Netherlands-based clinical-stage genetic medicines company developing therapies for severe neurological diseases, raised $60M in Series B funding. The round was led b... |
| 21.05.2023 | Riding the Wave of Innovation: Thriving Medical Startups in the Netherlands | Table of Contents show 1 AG5: Streamlining Skills Management 2 Vico Therapeutics: Pioneer in RNA Modulating Therapies 3 Villari: Leading in Structural Health Monitoring 4 Frame Cancer Therapeutics: Personalizing Cancer Vaccines 5 Healy... |
| 01.10.2020 | Dutch Vico Therapeutics strengthens leadership team with the appointment of Rupert Sandbrink as Chief Medical Officer and Anders Hinsby as Independent Director | |
| 29.07.2020 | Vico Therapeutics Raises $31M in Series A Financing | Vico Therapeutics Logo Vico Therapeutics, a Leiden, Netherlands-based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, raised $31m (€27m) in Series A financing round. The round was led... |
| - | Vico Therapeutics | “VICO Therapeutics - VICO Therapeutics” |